Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients – a claims data analysis
Abstract Background Recently, immune checkpoint inhibitors (ICIs) have driven profound changes in the treatment of non-small cell lung cancer (NSCLC). Their rapid integration into clinical routine is crucial for patient outcomes. However, prescribing patterns may not change immediately after authori...
Saved in:
| Main Authors: | Julia Walter, Blerina Resuli, Laura Sellmer, Diego Kauffmann-Guerrero, Toki Bolt, Chukwuka Eze, Jürgen Behr, Amanda Tufman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Public Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12889-025-23846-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of brigatinib following alectinib-induced-pneumonitis: Case report
by: Blerina Resuli, et al.
Published: (2025-01-01) -
Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor–related pneumonitis in lung cancer patients
by: Friederike Völter, et al.
Published: (2025-08-01) -
Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature
by: Blerina Resuli, et al.
Published: (2025-05-01) -
Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication
by: Blerina Resuli, et al.
Published: (2025-07-01) -
Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports
by: Blerina Resuli, MD, et al.
Published: (2024-12-01)